Cabozantinib for radioiodine-refractory differentiated thyroid cancer

被引：0
|
作者：
Chiapponi, Costanza [1 ]
Hartmann, Milan J. M. [1 ]
Hescheler, Daniel A. [2 ,3 ]
Alakus, Hakan [1 ]
机构：
[1] Univ Klinikum Koln AoR, Klin & Poliklin Allgemein Viszeral & Tumorchirurg, Kerpener Str 62, D-50937 Cologne, Germany
[2] Univ Klinikum Munster, Klin Nukl Med, Munster, Germany
[3] Westfalische Wilhelms Univ Munster, European Inst Mol Imaging EIMI, Munster, Germany
来源：
ONKOLOGE | 2021年 / 27卷 / 12期
关键词：
ASSOCIATION GUIDELINES;
D O I：
10.1007/s00761-021-01045-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1241 / 1242
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
    Shi, Bo
    Ma, Wenbiao
    Pan, Hongshuai
    Shi, Yang
    Zhang, Huan
    Xing, Shenghai
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Advanced Radioiodine-refractory differentiated Thyroid Cancer
    Spitzweg, Christine
    Auernhammer, Christoph J.
    Geisler, Julia
    Boeck, Stefan
    Heinemann, Volker
    Bartenstein, Peter
    Goeke, Burkhard
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2015, 140 (03) : 168 - 171
  • [3] Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
    Ovcaricek, Petra Petranovic
    Campenni, Alfredo
    de Keizer, Bart
    Deandreis, Desiree
    Kreissl, Michael C.
    Vrachimis, Alexis
    Tuncel, Murat
    Giovanella, Luca
    [J]. CANCERS, 2023, 15 (17)
  • [4] Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
    Hewett, Yvonne
    Ghimire, Subash
    Farooqi, Bilal
    Shah, Binay K.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (01) : 28 - 32
  • [5] THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Huang, W.
    Chen, L.
    Ting, J.
    Cao, V
    Sung, H.
    Yokokura, M.
    Wilson, L.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A886 - A886
  • [6] Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
    Kiyota, Naomi
    Robinson, Bruce
    Shah, Manisha
    Hoff, Ana O.
    Taylor, Matthew H.
    Li, Di
    Dutcus, Corina E.
    Lee, Eun Kyung
    Kim, Sung-Bae
    Tahara, Makoto
    [J]. THYROID, 2017, 27 (09) : 1135 - 1141
  • [7] Targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer (DTC)
    Herceg, Davorin
    Herceg, Gordana Horvatic
    [J]. PERIODICUM BIOLOGORUM, 2014, 116 (04) : 399 - 407
  • [8] Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
    Shen, Huize
    Zhu, Rui
    Liu, Yanyang
    Hong, Yangjian
    Ge, Jiaming
    Xuan, Jie
    Niu, Wenyuan
    Yu, Xuefei
    Qin, Jiang-Jiang
    Li, Qinglin
    [J]. DRUG RESISTANCE UPDATES, 2024, 72
  • [9] Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
    Weitzman, Steven P.
    Sherman, Steven, I
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 253 - +
  • [10] Treatment of Patients with Radioiodine-Refractory, differentiated Thyroid Cancer A Consensus Statement
    Lindner, C.
    Dierneder, J.
    Pall, G.
    Pirich, C.
    Hoffmann, M.
    Raderer, M.
    Becherer, A.
    Niederle, B.
    Lipp, R.
    Lind, P.
    Gallowitsch, H.
    Romeder, F.
    Virgolini, I.
    [J]. NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 125 - 130
12345